Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

In late February 2026, Merck reported a wave of positive late-stage data and regulatory milestones for KEYTRUDA-based combinations and other pipeline assets across kidney, ovarian and bladder cancers, ...

Merck (NYSE:MRK) is approaching phase 2 data for Winrevair in pulmonary hypertension. Results will focus on the 6 minute walk ...

RAHWAY, N.J. - Merck is officially adding an experimental flu prevention drug to its portfolio. The New Jersey-based pharmaceutical giant has completed its $9.2 billion acquisition of Cidara ...

German healthcare firm Merck KGaA is boosting investments in China, aiming for strategic collaborations with local companies.

Merck Group, the German pharmaceutical company, saw its Frankfurt-listed shares fall 10% on Tuesday morning after the company said it had decided to call off a Phase III trial of its cancer drug ...

Q4 2025 Press Conference Call March 5, 2026 4:00 AM ESTCompany ParticipantsAxel LoberBelén Garijo López - Chair of Executive Board ...

The company anticipates currency headwinds would continue to weigh on its earnings this year, as the life-sciences and ...

Add Yahoo as a preferred source to see more of our stories on Google. The logo of the pharmaceutical and chemical company Merck is displayed on flags on a building at its headquarters in Darmstadt.

Belén Garijo, Chair of the Executive Board and CEO of Germany's Merck Group, stated in an interview with Xinhua News Agency on the 5th that Merck Group has always placed great importance on the ...